UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 20 von 3655
Datensatz exportieren als...
BibTeX
Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study
Neurological sciences, 2015-10, Vol.36 (10), p.1869-1873
Teggi, R.
Colombo, B.
Gatti, O.
Comi, G.
Bussi, M.
2015
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Teggi, R.
Colombo, B.
Gatti, O.
Comi, G.
Bussi, M.
Titel
Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study
Ist Teil von
Neurological sciences, 2015-10, Vol.36 (10), p.1869-1873
Ort / Verlag
Milan: Springer Milan
Erscheinungsjahr
2015
Quelle
Psychology and Behavioral Sciences Collection
Beschreibungen/Notizen
Vestibular migraine (VM) is one of the most frequent causes of episodic vertigo, with a lifetime prevalence of 0.98 %. Prophylactic therapy includes calcium channel blockers, beta-blockers, antiepileptic drugs and antidepressants. We studied the association of cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevertan©) in a group of 22 patients affected by definite VM. Proposed therapy included one tablet twice a day for 1 month, which was repeated three times with 1 month of interval between drug intake; results were compared with those of a control group of 11 VM patients who asked to observe only lifestyle measures for migraine. The main outcome was the number of vertigo and headache crises in the 6 months before therapy and in the 6 months of follow-up. Subjects performing Arlevertan© presented during the 6 months of therapy a decrease of vertigo attacks from 5.3 to 2.1 and of headaches from 4.3 to 1.7 ( p < 0.0001); 68 % of these subjects reported a decrease of at least 50 % of vertigo attacks, while 63 % of headaches. Conversely, vertigo attacks decreased from 3.5 to 2.2 and headaches from 2.6 to 2 in patients observing only lifestyle; 18 % of these subjects reported a decrease of at least 50 % of vertigo crises and 27 % of headaches. Our data do not differ from those of previous works assessing efficacy of different prophylactic therapies for VM and reporting consistent reduction of vertigo spells in a rate of patients ranging from 60 and 80 %.
Sprache
Englisch
Identifikatoren
ISSN: 1590-1874
eISSN: 1590-3478
DOI: 10.1007/s10072-015-2270-6
Titel-ID: cdi_proquest_miscellaneous_1722174385
Format
–
Schlagworte
Adult
,
Calcium Channel Blockers - therapeutic use
,
Cinnarizine - therapeutic use
,
Dimenhydrinate - therapeutic use
,
Drug Combinations
,
Female
,
Follow-Up Studies
,
Histamine H1 Antagonists - therapeutic use
,
Humans
,
Male
,
Medicine
,
Medicine & Public Health
,
Migraine
,
Migraine Disorders - drug therapy
,
Migraine Disorders - physiopathology
,
Neurology
,
Neuroradiology
,
Neurosciences
,
Neurosurgery
,
Original Article
,
Psychiatry
,
Time Factors
,
Treatment Outcome
,
Vertigo - drug therapy
,
Vertigo - physiopathology
,
Vestibular Diseases - drug therapy
,
Vestibular Diseases - physiopathology
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX